These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 8420681)
1. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Kramer BS; Gohagan J; Prorok PC; Smart C Cancer; 1993 Jan; 71(2 Suppl):589-93. PubMed ID: 8420681 [TBL] [Abstract][Full Text] [Related]
2. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Gohagan JK; Prorok PC; Hayes RB; Kramer BS; Control Clin Trials; 2000 Dec; 21(6 Suppl):251S-272S. PubMed ID: 11189683 [TBL] [Abstract][Full Text] [Related]
4. Three-dimensional ultrasonography and power Doppler in ovarian cancer screening of asymptomatic peri- and postmenopausal women. Kurjak A; Prka M; Arenas JM; Sparac V; Merce LT; Corusic A; Ivancic-Kosuta M Croat Med J; 2005 Oct; 46(5):757-64. PubMed ID: 16158468 [TBL] [Abstract][Full Text] [Related]
5. Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Andriole GL Recent Results Cancer Res; 2014; 202():53-7. PubMed ID: 24531777 [TBL] [Abstract][Full Text] [Related]
6. Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Miller AB; Yurgalevitch S; Weissfeld JL; Control Clin Trials; 2000 Dec; 21(6 Suppl):400S-406S. PubMed ID: 11189691 [TBL] [Abstract][Full Text] [Related]
7. Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Weissfeld JL; Fagerstrom RM; O'Brien B; Control Clin Trials; 2000 Dec; 21(6 Suppl):390S-399S. PubMed ID: 11189690 [TBL] [Abstract][Full Text] [Related]
8. A different interpretation of the efficacy of lung cancer screening in the PLCO trial. Sagawa M; Nakayama T; Sobue T; Eur J Epidemiol; 2016 Feb; 31(2):211-2. PubMed ID: 26197850 [No Abstract] [Full Text] [Related]
9. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Hayes RB; Reding D; Kopp W; Subar AF; Bhat N; Rothman N; Caporaso N; Ziegler RG; Johnson CC; Weissfeld JL; Hoover RN; Hartge P; Palace C; Gohagan JK; Control Clin Trials; 2000 Dec; 21(6 Suppl):349S-355S. PubMed ID: 11189687 [TBL] [Abstract][Full Text] [Related]
10. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. Gohagan JK; Prorok PC; Kramer BS; Cornett JE J Urol; 1994 Nov; 152(5 Pt 2):1905-9. PubMed ID: 7523735 [TBL] [Abstract][Full Text] [Related]
11. Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial. Prorok PC; Wright P; Riley TR; Kramer BS; Berg CD; Gohagan JK Rev Recent Clin Trials; 2018; 13(4):257-273. PubMed ID: 29629665 [TBL] [Abstract][Full Text] [Related]
12. Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Stallings FL; Ford ME; Simpson NK; Fouad M; Jernigan JC; Trauth JM; Miller DS; Control Clin Trials; 2000 Dec; 21(6 Suppl):379S-389S. PubMed ID: 11189689 [TBL] [Abstract][Full Text] [Related]
13. Serum CA 125 combined with transvaginal ultrasonography for ovarian cancer screening. Roupa Z; Faros E; Raftopoulos V; Tzavelas G; Kotrotsiou E; Sotiropoulou P; Karanikola E; Skifta E; Ardavanis A In Vivo; 2004; 18(6):831-6. PubMed ID: 15646829 [TBL] [Abstract][Full Text] [Related]
14. Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: the first six years. Simpson NK; Johnson CC; Ogden SL; Gamito E; Trocky N; McGuire C; Martin J; Barrow S; Lamerato L; Flickinger LM; Broski KG; Engelhard D; Hilke C; Bonk J; Gahagan B; Gren LH; Childs J; Lappe K; Fouad M; Thompson J; Sullivan D; Control Clin Trials; 2000 Dec; 21(6 Suppl):356S-378S. PubMed ID: 11189688 [TBL] [Abstract][Full Text] [Related]
15. The National Cancer Institute Multi-Screening Trial. Prorok P Can J Oncol; 1994 Nov; 4 Suppl 1():98-9; discussion 100-1. PubMed ID: 8853500 [No Abstract] [Full Text] [Related]
16. Recruitment in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: the first phase of recruitment at Henry Ford Health System. Lamerato LE; Marcus PM; Jacobsen G; Johnson CC Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):827-33. PubMed ID: 18398023 [TBL] [Abstract][Full Text] [Related]
17. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK; J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007 [TBL] [Abstract][Full Text] [Related]
18. ACS releases updated guidelines on cancer screening. Lambert M Am Fam Physician; 2012 Sep; 86(6):571, 576-7. PubMed ID: 23062051 [No Abstract] [Full Text] [Related]
20. Prospective investigation of body mass index, colorectal adenoma, and colorectal cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Kitahara CM; Berndt SI; de González AB; Coleman HG; Schoen RE; Hayes RB; Huang WY J Clin Oncol; 2013 Jul; 31(19):2450-9. PubMed ID: 23715565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]